

Myung Sun Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3373394/publications.pdf>

Version: 2024-02-01

18
papers

84
citations

1684188

5
h-index

1588992

8
g-index

19
all docs

19
docs citations

19
times ranked

110
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistent challenges with treating multiple myeloma early. <i>Blood</i> , 2021, 137, 456-458.	1.4	17
2	Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 1207-1211.	5.2	12
3	Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals. <i>JAMA Network Open</i> , 2019, 2, e193981.	5.9	7
4	Approval and Coverage of Cancer Drugs in England, Canada, and the US. <i>JAMA Internal Medicine</i> , 2021, 181, 509.	5.1	7
5	Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. <i>European Journal of Cancer</i> , 2021, 155, 163-167.	2.8	7
6	Overall survival for oncology drugs approved for genomic indications. <i>European Journal of Cancer</i> , 2022, 160, 175-179.	2.8	6
7	The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. <i>JAMA Internal Medicine</i> , 2020, 180, 315.	5.1	5
8	Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature. <i>JAMA Internal Medicine</i> , 2021, , .	5.1	5
9	Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia. <i>Case Reports in Hematology</i> , 2022, 2022, 1-5.	0.4	5
10	US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation. <i>Cancer</i> , 2020, 126, 4270-4272.	4.1	3
11	Cancer screening: A modest proposal for prevention. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 157-160.	1.3	3
12	Quality of biomarker defined subgroups in <sc>FDA</sc> approvals of <sc>PD</sc>-1</sc> inhibitors 2014 to 2020. <i>International Journal of Cancer</i> , 2022, 150, 1905-1910.	5.1	3
13	When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 151-152.	3.5	1
14	New drugs and options can enhance patient outcomes: But can they also erode them?. <i>European Journal of Cancer</i> , 2021, 154, 1-3.	2.8	1
15	A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy. <i>Blood</i> , 2021, 138, 184-184.	1.4	1
16	A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2023, 64, 722-724.	1.3	1
17	Artificial intelligence and magnetic resonance imaging may not make cancer screening better. <i>Journal of Cancer Policy</i> , 2022, 31, 100314.	1.4	0
18	Addressing Sex Disparities in Academic Oncology. <i>JAMA Oncology</i> , 2022, , .	7.1	0